July 27, 2016

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-143)	ROVALPITUZUMAB TESIRINE
PRONUNCIATION	roe val" pi tooz' ue mab tes sir' een
THERAPEUTIC CLAIM	Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(protein DLL3 (delta-like ligand 3)) (human-*Mus musculus* monoclonal sc0001 heavy chain), disulfide with human-*Mus musculus* monoclonal sc0001 κ-chain, dimer, thioether with *N*-[31-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-*N*-[4-[[[[(11*S*,11a*S*)-8-[[5-[[(11a*S*)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-10(5*H*)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide

2. Immunoglobulin G1-kappa, anti-(human delta-like protein 3 (drosophila delta homolog 3, delta 3)); humanized monoclonal antibody: γ1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-18*1 (87%) –(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 {CH3 K^{107}>del(448)} (119-447)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-15*01 (87%) –IGKJ2*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (227-227'':230-230'')-bisdisulfide; an average of two cysteine residues involved in inter-chain disulfide bridges are *S*-substituted with tesirine radical

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	NYGMNWVRQA	PGQGLEWMGW	50
INTYTGEPTY	ADDFKGRVTM	TTDTSTSTAY	MELRSLRSDD	TAVYYCARIG	100
DSSPSDYWGQ	GTLVTVSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTQTYI	200
CNVNHKPSNT	KVDKKVEPKS	CDKTHTCPPC	PAPELLGGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLPPSRDELT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTTPPVLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK	SLSLSPG	447

Light chain

EIVMTQSPAT	LSVSPGERAT	LSCKASQSVS	NDVVWYQQKP	GQAPRLLIYY	50'
ASNRYTGIPA	RFSGSGSGTE	FTLTISSLQS	EDFAVYYCQQ	DYTSPWTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22"-96"	23'-88'	23'"-88'"	134'-194'	134'"-194'"	145-201	145"-201"
214'-221*	214'"-221"*	227-227"*	230-230"*	262-322	262"-322"	368-426	368"-426"

* an average of one interchain disulfide bond is reduced and the two cysteines *S*-substituted with tesirine.

Potential modified residues

Q 1, 1" Pyroglutamic acid (Glp)



C 214',214'" ; 221,221" ; 227,227" ; 230,230" "*S*-tesirine Cysteine"



Glycosylation sites (N)

Asn-298 Asn-298"

MOLECULAR FORMULA	$C_{6416}H_{9894}N_{1698}O_{2028}S_{46}$ $(C_{75}H_{102}N_9O_{23})_n$ (peptide)
MOLECULAR WEIGHT	147.0 kDa (peptide)
TRADEMARK	None
SPONSOR	AbbVie Inc.
CODE DESIGNATIONS	SC0002
CAS REGISTRY NUMBER	1613313-09-9
UNII	P256HB60FF
WHO NUMBER	10141

gbk